Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.
Clin Lymphoma Myeloma Leuk
; 11(2): 242-5, 2011 Apr.
Article
em En
| MEDLINE
| ID: mdl-21575930
ABSTRACT
BACKGROUND:
Reduced-intensity conditioning allogeneic transplantation for myeloma is associated with lower non-relapse mortality and higher relapse rates in comparison with myeloablative conditioning transplants. PATIENTS ANDMETHODS:
We have retrospectively audited 19 patients with myeloma or primary plasma cell leukemia who received allogeneic transplantation with a uniform alemtuzumab-based reduced-intensity conditioning protocol. These patients had not been treated with bortezomib or lenalidomide before transplantation.RESULTS:
The treatment-related mortality at 1 year was (4/19) 21% with low incidence of graft-versus-host disease (6%) and 2-year progression-free survival and overall survival rates of 35% and 42%, respectively.CONCLUSION:
Progression-free survival in this cohort of patients is comparable to previously published data of reduced-intensity conditioning allogeneic transplantation in myeloma. However, there is no plateau observed on the survival curves with a significant transplant-related mortality of 21%. Therefore, alemtuzumab-based allogeneic transplantation cannot be recommended as standard practice outside of clinical trials for treatment of myeloma.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia Plasmocitária
/
Transplante de Células-Tronco Hematopoéticas
/
Condicionamento Pré-Transplante
/
Anticorpos Monoclonais
/
Anticorpos Antineoplásicos
/
Mieloma Múltiplo
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article